Pathology in Cancer Drug Development among Sessions at CHI’s Tissue-Based Diagnostics Conference

Pathology in cancer drug development is one of the sessions taking place at CHI’s inaugural Innovative Tissue-Based Diagnostics: Decoding Cancer & Other Maladies conference being held on June 4-5, 2012 at the Loews Hotel in Philadelphia, PA.
 
March 14, 2012 - PRLog -- The conference is designed to designed to feature recent breakthroughs in the field of pathology such as testing for predictive cancer biomarkers, decoding cancer molecular profiles, next generation sequencing, circulating tumor cells, etc.

Pathology in Cancer Drug Development Session Schedule:

Monday, June 4 (1:30-5:30 pm)

1:30-2:00
Pathology Contributions to Pharma R&D: Enabling Key Intersections between Scientific Discovery and Tissue Diagnostics
John Lowe, M.D., Senior Director of Pathology, Genentech

2:00-2:30
Characterization and Clinical Validation of an Immunohistochemical Assay for MET in NSCLC
Hartmut Koeppen, M.D., Ph.D., Staff Pathologist, Genentech

2:30-3:00
Chasing the Holy Grail - Towards Pathway Analysis of Circulating Tumor Cells
Arndt Schmitz, Ph.D., Senior Scientist, Global Biomarker Research, Bayer Pharma AG

3:00-3:30
Sponsored presentation

3:30-4:00
Refreshment Break  with Exhibit & Poster Viewing

4:00-4:30
Nuclear Heat-Shock Factor 1 (HSF1) as a Predictor of Poor Prognosis in Breast Cancer.
Tan A. Ince, M.D., Ph.D., Assistant Professor, Pathology; Director, Tumor Stem Cell Division; Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine

4:30-5:00
microRNAs as Potential Biomarkers in Cancer
Laura J. Tafe, M.D., Assistant Director, Molecular Pathology, Assistant Professor, Department of Pathology, Dartmouth-Hitchcock Medical Center

5:00-5:30
mTOR Pathway in Urologic Malignancies: A Therapeutic Target and a Potential Progonsticator
George Netto, M.D., Associate Professor,Pathology, Urology and Oncology, Johns Hopkins University School of Medicine

In the other two sessions, CHI’s speakers will address molecular pathology as the driving force for personalized oncology and bridging radiology-pathology divide.

View additional presentations and register at http://www.healthtech.com/tdx
Advance registration discount deadline is April 27, 2012.

About Cambridge Healthtech Institute (www.chicorporate.com)

CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
End
Cambridge Healthtech Institute News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share